Biocryst Pharmaceuticals Inc

NASDAQ: BCRX
$4.21
-$0.17 (-3.9%)
Closing price April 24, 2024
Biocryst Pharmaceuticals Inc is a biotechnology firm focused on developing treatments for rare diseases. It offers RAPIVAB, RAPIACTA, and PERAMIFLU, which are brands of peramivir injection for acute influenza, and ORLADEYO, an oral treatment for hereditary angioedema. The company is also working on BCX10013, targeting complement-mediated diseases. Founded in 1986 and based in Durham, North Carolina, Biocryst collaborates with various global institutions and companies to advance its research and development efforts.
BioCryst Pharmaceuticals shares were crushed after it announced results from OPuS-2 for the treatment of hereditary angioedema attacks.
For the third straight week, insider selling has been nonexistent, while the insider buyers have taken advantage of the market sell-off.
Jefferies is out with its first group of growth stocks to buy this year, and the list has not only some timely picks, but companies that have been knocked to levels that are providing some of the...
The top analyst calls for Wednesday, January 6, 2016, include Bluebird Bio, Check Point Software, Comcast, Eli Lilly, Hyatt Hotels, Lockheed Martin and Rite Aid.
Pharmaceutical companies generally are involved in the lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk to a great amount of risk...
24/7 Wall St. has collected several big FDA decisions coming up in the month of November.
Friday's top analyst upgrades, downgrades and initiations include AT&T, BioCryst Pharmaceuticals, Eli Lilly, Facebook, Flextronics, Gap and Tesla Motors.
The most recent analyst call by Merrill Lynch for BioCryst Pharmaceuticals may be very misunderstood for what it is.
The health care sector and biotech in particular have been on fire so far in 2015, but some biotech stocks in the group just are not carrying their weight.
Within the past week, two Ebola-related companies are showing renewed optimism for their positions, whether it is securing a contract or raising capital.
At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.
Some Ebola-related stocks had been heavily shorted as they were considered by many investors as the next would-be stock bubble from a major news event.
Source: ThinkstockJust when you thought the Ebola virus outbreak risk was dwindling down… Fresh headlines from Dow Jones and the New York post have put the markets on Ebola watch all over again....
Some of the Ebola high-flying stocks saw their share prices crater on Monday as Ebola fears are subsiding for several reasons.
The sad news that Ebola patient Thomas Eric Duncan has died in a Dallas hospital now raises fears that Ebola drugs might not be a cure-all for patients.